{
  "abstract": "Background The pathogenesis of liver fibrosis centres on the activation of hepatic stellate cells (HSCs). Adenosine-to-inosine RNA editing, primarily catalysed by adenosine deaminase acting on RNA1 (ADAR1), is the most prevalent post-transcriptional modification that increases transcriptome diversity.Objective This study aims to elucidate the role of ADAR1-imposed RNA editome in HSC activation and to determine the therapeutic potential of targeting ADAR1 for liver fibrosis.Design ADAR1 expression was measured in fibrotic human and mouse livers, as well as in primary human and mouse HSCs. Adar1 loss-of-function effect was evaluated in Adar1 f/f/Cre-ER, Adar1△HSC and Adar1i△HSC mice, whereas viral infection with Ad-Adar1 was employed in gain-of-function studies. Adar1△HSCIfih1−/−- and Adar1△HSCIfnar△HSC mice were used for mechanistic studies. An ADAR1 inhibitor and HSC-selective RNAi were used for therapeutic evaluations.Results ADAR1 is decreased in human and mouse fibrotic livers and activated HSCs. HSC-specific ablation or pharmacological inhibition of ADAR1 ameliorated HSC activation and liver fibrosis. In contrast, forced expression of ADAR1, but not its editing-deficient mutant, exacerbated HSC activation. Mechanistically, ADAR1 ablation accumulated double-stranded RNA and activated HSC-intrinsic innate immunity in a melanoma differentiation-associated gene 5-dependent manner. Interferon-β was identified as a key antifibrotic effector via the activation of the JAK1/2 pathway. RNA editome analysis revealed the Col3a1 3’ UTR as a novel ADAR1 editing target, leading to increased collagen production.Conclusion ADAR1-imposed RNA editome suppresses HSC-intrinsic innate immunity and promotes collagen production, leading to aggravated HSC activation and liver fibrosis. Targeting ADAR1 with its pharmacological inhibitor or HSC-selective RNAi shows great promise in treating liver fibrosis.",
  "authors": [
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Yue Xi"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Lingyi Liu"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Jong-Won Kim"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Min Zhang"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Xiaofei Wang"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Aizat Abdirassil"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Meishu Xu"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Songrong Ren"
    },
    {
      "affiliations": [
        "Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Qingde Wang"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Da Yang"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Pengfei Xu"
    },
    {
      "affiliations": [
        "Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA",
        "Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Wen Xie"
    }
  ],
  "title": "Targeting ADAR1-mediated RNA editing inhibits hepatic stellate cell activation and liver fibrosis by enhancing HSC-intrinsic innate immunity",
  "uid": "90a55373-00be-5fe6-b9bc-987d610aa059"
}